Waters Corp
About: Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions.
Employees: 7,600
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
185% more call options, than puts
Call options by funds: $33.4M | Put options by funds: $11.7M
33% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 8 (+2) [Q1 2025]
23% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 62
6% more repeat investments, than reductions
Existing positions increased: 276 | Existing positions reduced: 261
0% less funds holding
Funds holding: 745 [Q4 2024] → 744 (-1) [Q1 2025]
0.63% less ownership
Funds ownership: 95.91% [Q4 2024] → 95.28% (-0.63%) [Q1 2025]
1% less capital invested
Capital invested by funds: $21.1B [Q4 2024] → $20.8B (-$285M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$350
2%
upside
Avg. target
$386
13%
upside
High target
$460
34%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Baird Catherine Ramsey | 9%upside $374 | Outperform Maintained | 7 May 2025 |
UBS Elizabeth Garcia | 5%upside $360 | Neutral Maintained | 7 May 2025 |
Barclays Luke Sergott | 2%upside $350 | Equal-Weight Maintained | 10 Apr 2025 |
Keybanc Paul Knight | 34%upside $460 | Overweight Upgraded | 31 Mar 2025 |
Financial journalist opinion
Based on 7 articles about WAT published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Here's Why Waters (WAT) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 week ago
Waters (WAT) Up 2.2% Since Last Earnings Report: Can It Continue?
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
Neutral
PRNewsWire
1 week ago
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass.
Positive
Zacks Investment Research
2 weeks ago
Why Waters (WAT) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
PRNewsWire
2 weeks ago
Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality
News Summary Enables measurements up to 2 days earlier for antibody titers for both clone selection and bioprocess monitoring.1 Provides up to 7x improvements in sensitivity with novel high efficiency particles.2 Delivers 2x more attribute information with simplified multi-attribute workflows.3 MILFORD, Mass. , May 28, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements.
Neutral
PRNewsWire
3 weeks ago
Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio
MILFORD, Mass. , May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies.
Neutral
PRNewsWire
4 weeks ago
Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass. , May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Positive
Reuters
1 month ago
Waters Corp's India business boosted by rush for weight-loss drugs
U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers in India rushing to develop their versions of popular weight-loss drugs, a senior executive told Reuters.
Positive
Zacks Investment Research
1 month ago
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.
Positive
Seeking Alpha
1 month ago
Waters Corporation: Still A Hold After Q1 Earnings
Waters Corporation's stock remains a "Hold" due to high valuation multiples, despite a 35% increase in stock price and improved business performance. The company reported solid Q1 2025 results, with 3.9% revenue growth and 18% EPS growth, but valuation remains above historical averages. Management is optimistic about future growth, citing opportunities in the Indian market, GLP-1 testing, and pricing strategies, expecting high single-digit revenue growth.
Charts implemented using Lightweight Charts™